Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Theta-Burst-Stimulation in Recurrent Stroke Recovery

25. November 2019 aktualisiert von: Christian Grefkes, University Hospital of Cologne
The present study aims at investigating the effects of intermittent theta-burst stimulation (iTBS) for motor recovery in recurrent stroke patients. Therefore a daily intervention of repetitive transcranial magnetic stimulation over 8 days combined with subsequent physiotherapy is compared to a control condition, sham stimulation combined with subsequent physiotherapy. Motor function, degree of disability and quality of life are examined in order to evaluate the effects of iTBS in the rehabilitation of recurrent stroke patients in the first weeks and after three months.

Studienübersicht

Detaillierte Beschreibung

To date, the majority of neuromodulation approaches aiming at improving motor recovery after stroke are limited to patients with first-ever ischemic stroke. Therefore, rehabilitation of recurrent stroke mainly includes physiotherapy and occupational therapy. Yet, particular these patients retain movement impairment relevant for activities of daily living.

By using repetitive transcranial magnetic stimulation (rTMS), it is possible to promote recovery of connectivity between brain regions, particularly after stroke and thereby improve motor performance. Previous data indicate that intermittent theta-burst stimulation (iTBS), a protocol of neuromodulation, enhances the effects of subsequent motor training in early rehabilitation after stroke.

The current study aims at investigating whether daily repetitive transcranial magnetic stimulation over 8 days combined with subsequent physiotherapy leads to better motor recovery in recurrent stroke, compared to control condition, physiotherapy after sham stimulation. Motor function, degree of disability and quality of life are examined in order to evaluate the effects of iTBS in the rehabilitation of recurrent stroke patients in the first weeks and after three months.

Studientyp

Interventionell

Einschreibung (Voraussichtlich)

60

Phase

  • Phase 2

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

      • Cologne, Deutschland, 50937
        • Christian Grefkles

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

40 Jahre bis 90 Jahre (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  • written consent
  • age: 40-90 years
  • recurrent stroke
  • hemiparesis with impaired hand motor function

Exclusion Criteria:

  • Subjects who are legally detained in an official institute (§20 MPG)
  • Electronic implants or ferromagnetic Implants located in the head, neck or thorax (e.g. clips, intracranial shunt, artificial heart valve, pacemaker)
  • Medication pump (e.g. insulin pump)
  • Metal splinters in eye or head
  • Pregnancy / breastfeeding
  • Severe Neurodegenerative disease
  • Severe Neuroinflammatory disease
  • History of seizures / epilepsy
  • Physical addiction to alcohol, medication, or drugs (excluded: nicotine)
  • Insufficient compliance
  • Present or past malignant tumor involving the central nervous system
  • Severe Psychiatric disease
  • Frequent medication with benzodiazepines, high-potency antipsychotics or tricyclic antidepressants before hospitalization or long-term during hospitalization

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Grundlegende Wissenschaft
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Verdreifachen

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Aktiver Komparator: Real-iTBS
Intermittent theta-burst-stimulation (iTBS) protocol
Sham stimulation
Schein-Komparator: Sham-iTBS
Intermittent theta-burst-stimulation (iTBS) protocol
Sham stimulation

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Relative grip force
Zeitfenster: 3 months after enrollment
grip force as measured with vigorimeter
3 months after enrollment

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Relative grip force
Zeitfenster: After 8 days of intervention, and 3 months of enrollment
Grip force as measured with vigorimeter
After 8 days of intervention, and 3 months of enrollment
Motor function
Zeitfenster: After 8 days of intervention, and 3 months of enrollment
Action Research Arm Test, ARAT
After 8 days of intervention, and 3 months of enrollment
Motor function
Zeitfenster: After 8 days of intervention, and 3 months of enrollment

Fugl-Meyer Motor Scale of the upper extremity, FM The Fugl-Meyer Assessment scale is an ordinal scale that has 3 points for each item. A zero score is given for the item if the subject cannot do the task. A score of 1 is given when the task is performed partially and a score of 2 is given when the task is performed fully.

Minimum score in upper limb = 0 Maximum score in upper limb = 66, Subscales are summed

After 8 days of intervention, and 3 months of enrollment
Stroke severity
Zeitfenster: After 8 days of intervention, and 3 months of enrollment

National Instituts of Health Stroke Scale, NIHSS The NIHSS is composed of 11 items, each of which scores a specific ability between a 0 and 4. For each item, a score of 0 typically indicates normal function in that specific ability, while a higher score is indicative of some level of impairment.

The individual scores from each item are summed in order to calculate a patient's total NIHSS score. The maximum possible score is 42, with the minimum score being a 0.

After 8 days of intervention, and 3 months of enrollment
Degree of disability
Zeitfenster: After 8 days of intervention, and 3 months of enrollment
Modified Rankin Scale, mRS The scale runs from 0-6, running from perfect health (0) without symptoms to death (6).
After 8 days of intervention, and 3 months of enrollment
Motor cortex excitability/ Motor evoked potential
Zeitfenster: After 8 days of intervention, and 3 months of enrollment
Motor evoked potential (MEP) induced by stimulation of the affected motor cortex
After 8 days of intervention, and 3 months of enrollment
Motor cortex excitability/ Resting motor threshold
Zeitfenster: After 8 days of intervention, and 3 months of enrollment
Resting motor threshold as measured by stimulation of the affected motor cortex, RMT
After 8 days of intervention, and 3 months of enrollment
Motor cortex excitability/ Short-interval intracortical inhibition
Zeitfenster: After 8 days of intervention, and 3 months of enrollment
Short-interval intracortical inhibition Short-interval intracortical inhibition (SICI) is a widely used paired-pulse transcranial magnetic stimulation (TMS) measure to assess inhibition in human motor cortex
After 8 days of intervention, and 3 months of enrollment
Motor cortex excitability/ Ipsilateral silent period
Zeitfenster: After 8 days of intervention, and 3 months of enrollment
Ipsilateral silent period The ipsilateral silent period (iSP) is supposed to be a specific marker of transcallosal motor inhibition. Measured by a short attenuation or interruption of ongoing voluntary electromyographic (EMG) activity in hand muscles induced by focal TMS of the ipsilateral M1.
After 8 days of intervention, and 3 months of enrollment
Quality of life
Zeitfenster: After 8 days of intervention, and 3 months of enrollment
EuroQol 5D questionnaire, EQ-5D
After 8 days of intervention, and 3 months of enrollment
Activities of daily living at admission and discharge in external rehabilitation facility
Zeitfenster: After 8 days of intervention, and 3 months of enrollment
Barthel-Index (BI) scores as documented by external rehabilitation facility The Barthel scale is an ordinal scale used to measure performance in activities of daily living (ADL). A higher number is associated with a greater likelihood of being able to live at home with a degree of independence following discharge from hospital. The scale yield a score of 0-100.
After 8 days of intervention, and 3 months of enrollment
Days of rehabilitation after intervention phase
Zeitfenster: 3 months after enrollment
Days of rehabilitation after intervention phase as documented by external rehabilitation facility
3 months after enrollment

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Ermittler

  • Hauptermittler: Christian Grefkes, MD, University Hospital Cologne

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

11. Januar 2018

Primärer Abschluss (Voraussichtlich)

1. November 2021

Studienabschluss (Voraussichtlich)

1. November 2021

Studienanmeldedaten

Zuerst eingereicht

3. November 2017

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

6. November 2017

Zuerst gepostet (Tatsächlich)

9. November 2017

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

27. November 2019

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

25. November 2019

Zuletzt verifiziert

1. November 2019

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

NEIN

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Klinische Studien zur Magstim Super Rapid2 System

Abonnieren